Literature DB >> 29488625

Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation.

Zhen Bian1, Ahmed Mansour Abdelaal1, Lei Shi1, Hongwei Liang1, Lanqiao Xiong1, Koby Kidder1, Mahathi Venkataramani1, Courtney Culpepper1, Ke Zen2, Yuan Liu1.   

Abstract

Although previous reports suggest that tumor-induced myeloid-derived suppressor cells (MDSC) inhibit T cells by L-arginine depletion through arginase-1 activity, we herein show that arginase-1 is neither inherently expressed in MDSC nor required for MDSC-mediated inhibition. Employing Percoll density gradients, large expansions of MDSC in the bone marrow of tumor-bearing mice were isolated and demonstrated potent inhibition in T-cell proliferation activated by TCR-ligation, Concanavalin A, PMA plus ionomycin, or IL-2. Despite demonstrating characteristic immunosuppressive capacity, these MDSC exhibit no arginase-1 expression and/or exert their inhibitory effects independent of arginase-1 activity. However, arginase-1 expression in MDSC can be induced by exposure to TCR-activated T cells or their culture medium, but not T cells activated by other means or growing tumor cells. Further investigation reveals multiple cytokines secreted by TCR-activated T cells as orchestrating two signaling-relay axes, IL-6-to-IL-4 and GM-CSF/IL-4-to-IL-10, leading to arginase-1 expression in MDSC. Specifically, IL-6 signaling increases IL-4R, enabling IL-4 to induce arginase-1 expression; similarly, GM-CSF in concert with IL-4 induces IL-10R, allowing IL-10-mediated induction. Surprisingly, our study indicates that induction of arginase-1 expression is not conducive to the critical MDSC-mediated inhibition toward T cells, which is rather dependent on direct cell contacts undiminished by PD-L1 blockade or SIRPα deficiency.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Arginase-1; GM-CSF; IL-10; IL-4; Myeloid-derived suppressor cell

Mesh:

Substances:

Year:  2018        PMID: 29488625      PMCID: PMC5997508          DOI: 10.1002/eji.201747355

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  50 in total

Review 1.  Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Authors:  Augusto C Ochoa; Arnold H Zea; Claudia Hernandez; Paulo C Rodriguez
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

Authors:  M Munder; K Eichmann; J M Morán; F Centeno; G Soler; M Modolell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

3.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

4.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

5.  Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness.

Authors:  J Deshane; J W Zmijewski; R Luther; A Gaggar; R Deshane; J-F Lai; X Xu; M Spell; K Estell; C T Weaver; E Abraham; L M Schwiebert; D D Chaplin
Journal:  Mucosal Immunol       Date:  2011-04-06       Impact factor: 7.313

Review 6.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

7.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

Authors:  Gary Kohanbash; Kayla McKaveney; Masashi Sakaki; Ryo Ueda; Arlan H Mintz; Nduka Amankulor; Mitsugu Fujita; John R Ohlfest; Hideho Okada
Journal:  Cancer Res       Date:  2013-09-12       Impact factor: 12.701

10.  L-arginine deprivation impairs Leishmania major-specific T-cell responses.

Authors:  Markus Munder; Beak-San Choi; Matthew Rogers; Pascale Kropf
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

View more
  22 in total

1.  Arginase-1 Expression in Myeloid Cells Regulates Staphylococcus aureus Planktonic but Not Biofilm Infection.

Authors:  Kelsey J Yamada; Cortney E Heim; Amy L Aldrich; Casey M Gries; Anna G Staudacher; Tammy Kielian
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

2.  Murine myeloid derived suppressor cells possess a range of suppressive mechanisms-Granzyme B is not among them.

Authors:  Ellis Tibbs; Xuefang Cao
Journal:  Cancer Immunol Immunother       Date:  2022-02-07       Impact factor: 6.630

Review 3.  Reprogramming of sentinel lymph node microenvironment during tumor metastasis.

Authors:  Yen-Liang Li; Wen-Chun Hung
Journal:  J Biomed Sci       Date:  2022-10-20       Impact factor: 12.771

4.  Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy.

Authors:  Zhen Bian; Lei Shi; Koby Kidder; Ke Zen; Charlie Garnett-Benson; Yuan Liu
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

Review 5.  Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

6.  Ex Vivo-Induced Bone Marrow-Derived Myeloid Suppressor Cells Prevent Corneal Allograft Rejection in Mice.

Authors:  Jun Zhu; Takenori Inomata; Keiichi Fujimoto; Koichiro Uchida; Kenta Fujio; Ken Nagino; Maria Miura; Naoko Negishi; Yuichi Okumura; Yasutsugu Akasaki; Kunihiko Hirosawa; Mizu Kuwahara; Atsuko Eguchi; Hurramhon Shokirova; Ai Yanagawa; Akie Midorikawa-Inomata; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-06-01       Impact factor: 4.799

7.  Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases.

Authors:  Ahmed M Abdelaal; Andrea L Kasinski
Journal:  NAR Cancer       Date:  2021-07-20

Review 8.  Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy.

Authors:  Houhui Shi; Kai Li; Yanghong Ni; Xiao Liang; Xia Zhao
Journal:  Front Cell Dev Biol       Date:  2021-07-14

9.  Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells.

Authors:  Zhaofei Li; Yanfang Zhao; Zhu Chen; Jannet Katz; Suzanne M Michalek; Yuhong Li; Ping Zhang
Journal:  Mol Immunol       Date:  2021-07-16       Impact factor: 4.174

Review 10.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.